Back | Next |
home / stock / aldr / aldr message board
Subject | By | Source | When |
---|---|---|---|
Nice 6% gainer today!!! | Investor100 | investorshub | 04/13/2016 11:29:47 PM |
Alder Presents Preclinical Data for ALD1613 at $ENDO 2016 | Investor100 | investorshub | 04/04/2016 1:11:30 AM |
Our March highlight just gained 50%: Alder Biopharmaceuticals | nyctraydr | investorshub | 03/29/2016 2:47:28 PM |
http://finance.yahoo.com/news/alder-reports-phase-2b-trial-110000104.html | north40000 | investorshub | 03/28/2016 3:53:52 PM |
Monster Run On Huge News Up 57% | Investor100 | investorshub | 03/28/2016 2:49:12 PM |
Alder is a Risky Allocation in a Crowded, | nyctraydr | investorshub | 02/08/2016 4:09:09 PM |
Cramer @ $ALDR | Investor100 | investorshub | 01/30/2016 5:17:45 PM |
$ALDR @ Stockcharts | Investor100 | investorshub | 01/16/2016 5:52:35 PM |
$ALDR @ JPMorgan Healthcare Conference Presentation | Investor100 | investorshub | 01/16/2016 5:48:34 PM |
Migraine Statistics | Investor100 | investorshub | 01/16/2016 4:54:12 PM |
CEO @ $ALDR Interview | Investor100 | investorshub | 01/16/2016 4:40:56 PM |
$CEO @ Mad Money | Investor100 | investorshub | 01/15/2016 7:08:48 PM |
$ALDR @ Stockcharts | Investor100 | investorshub | 12/06/2015 4:10:50 PM |
Here is What Hedge Funds Think About Alder | Investor100 | investorshub | 12/06/2015 4:08:59 PM |
$ALDR @ Stockcharts | Investor100 | investorshub | 11/11/2015 11:56:47 PM |
$ALDR Bought the dips .... | Investor100 | investorshub | 11/09/2015 1:43:59 AM |
$ALDR @ Stockcharts | Investor100 | investorshub | 10/20/2015 8:44:11 PM |
Moving Up @ $ALDR | Investor100 | investorshub | 09/05/2015 1:37:02 AM |
Upward @ $ALDR | Investor100 | investorshub | 07/29/2015 1:27:52 AM |
Dip @ $ALDR | Investor100 | investorshub | 07/18/2015 5:36:31 PM |
News, Short Squeeze, Breakout and More Instantly...
Alder BioPharmaceuticals Inc. Company Name:
ALDR Stock Symbol:
NASDAQ Market:
Alder BioPharmaceuticals Inc. Website:
Biotech is in the doldrums. The SPDR S&P Biotech ETF declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...
BOTHELL, Wash., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing therapeutic antibodies for the treatment of migraine, today announced dosing of the first patient in a Phase 1 clinical study to evaluate ALD191...
Shares of Alder Biopharmaceuticals (NASDAQ: ALDR) jumped 111% in September, according to data provided by S&P Global Market Intelligence , after the biotech said it will be acquired by Lundbeck. Lundbeck, a fairly large drugmaker in Denmark, is after Alder Pharmaceuticals' migraine m...